EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC-ND 4.0

Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma

Rui Chen, Zhiping Wang, Tianzhu Lu, Yuzhen Liu, Yulong Ji, Yilin Yu, Fangfang Tou, Shanxian Guo iD

Thoracic Cancer · 2023-04 · 14 (10) · 893-912

DOI: 10.1111/1759-7714.14822 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Thoracic Cancer, online erschienen am 24.02.2023. Verfasst von Rui Chen und 7 weiteren Autor:innen. Beteiligte Einrichtung: Graduate School, Medical College of Nanchang University, Nanchang, China. Hauptthemen laut MEDLINE: Adenocarcinoma of Lung, Lung Neoplasms. Die Arbeit wurde bisher 8-mal zitiert (Crossref) und nennt 49 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC-ND 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Background

The budding uninhibited by benzimidazoles (BUB) family is involved in the cell cycle process as mitotic checkpoint components. Abnormal proliferation is a vital process in the development of lung adenocarcinoma (LUAD). Nevertheless, the roles of BUB1 in LUAD remain unclear. In this study, we evaluated the prognostic value and biological functions of BUB1 in LUAD using data from The Cancer Genome Atlas (TCGA), Gene Expression Omnibus (GEO), clinical LUAD samples, and in vitro experiments.

Methods

The expression, prognostic significance, functions, immune infiltration, and methylation of BUB1 in LUAD were comprehensively analyzed using TCGA, GEO, Gene Expression Profiling Interactive Analysis, Metascape, cBioPortal, MethSurv, and cancerSEA databases. Furthermore, we performed a battery of in vitro experiments and immunohistochemistry (IHC) to verify the bioinformatics results.

Results

Multivariate analysis revealed that BUB1 overexpression was an independent prognostic factor (hazard ratio = 1.499, p = 0.013). Functional enrichment analysis showed that BUB1 was correlated with cell cycle, proliferation, DNA repair, DNA damage, and invasion ( p < 0.05). Finally, in vitro experiments showed that downregulation of BUB1 inhibited the proliferation, migration, and invasion of LUAD cells and promoted LUAD cell apoptosis. IHC also showed that BUB1 was overexpressed in LUAD ( p < 0.001) and was significantly associated with poor prognosis ( p < 0.001).

Conclusions

Our bioinformatics and IHC analyses revealed that BUB1 overexpression was an adverse prognostic factor in LUAD. In vitro experiments demonstrated that BUB1 promoted tumor cell proliferation, migration, and invasion in LUAD. These results indicated that BUB1 was a promising biomarker and potential therapeutic target in LUAD.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Adenocarcinoma of LungLung NeoplasmsHumansPhenotypeBenzimidazolesPrognosis

Stichwörter der Autor:innen

budding uninhibited by benzimidazoles 1cell cycleimmunohistochemistrylung adenocarcinomamethylation

Substanzen

Benzimidazoles

Autor:innen und Institutionen

  • Graduate School, Medical College of Nanchang University, Nanchang, China.
  • Jiangxi Key Laboratory of Translational Research for Cancer, Jiangxi Clinical Research Center for Cancer, Jiangxi Cancer Hospital, The Second Affiliated Hospital of Nanchang Medical College, Nanchang, China.
  • Fujian Medical University, Fuzhou, China.
  • Jiangxi Provincial People's Hospital, The First Affiliated Hospital of Nanchang Medical College, Nanchang, China.

ORCID-Profile: Shanxian Guo

Zitieren

APA

Chen, R., Wang, Z., Lu, T., Liu, Y., Ji, Y., Yu, Y., Tou, F., & Guo, S. (2023). Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. Thoracic Cancer, 14(10), 893-912. https://doi.org/10.1111/1759-7714.14822

Vancouver

Chen R, Wang Z, Lu T, Liu Y, Ji Y, Yu Y, et al. Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma. Thoracic Cancer. 2023;14(10):893-912. doi:10.1111/1759-7714.14822

BibTeX
@article{Chen2023,
  author = {Chen, Rui and Wang, Zhiping and Lu, Tianzhu and Liu, Yuzhen and Ji, Yulong and Yu, Yilin and Tou, Fangfang and Guo, Shanxian},
  title = {Budding uninhibited by benzimidazoles 1 overexpression is associated with poor prognosis and malignant phenotype: A promising therapeutic target for lung adenocarcinoma},
  journal = {Thoracic Cancer},
  year = {2023},
  volume = {14},
  number = {10},
  pages = {893--912},
  doi = {10.1111/1759-7714.14822}
}
Kostenlos starten →